| 11/25/2008 | CVHY | Moody's lowers Lazard outlook to stable
|
| 5/2/2008 | CVHYIG | Lazard to buy back its 6.12% notes at 100.5
|
| 4/17/2008 | CVHY | Moody's affirms Lazard
|
| 4/9/2008 | CV | Fitch affirms Lazard
|
| 6/18/2007 | CVHY | Moody's rates Lazard notes Ba1
|
| 6/18/2007 | CVHY | Fitch rates Lazard notes BBB-
|
| 3/19/2007 | CVHY | Moody's lifts Lazard view to positive
|
| 3/16/2007 | CV | Fitch boosts Lazard to BB+
|
| 3/22/2006 | CV | Fitch affirms Lazard
|
| 5/17/2005 | CV | Market Commentary: TOP Tankers deal re-sunk; Exide crashes; Calpine crumbles; Ford, GM, auto suppliers mixed
|
| 5/10/2005 | CV | Market Commentary: GM, Ford sputter but drive volume in Tower Auto, American Axle; TOP Tankers delayed
|
| 5/5/2005 | CV | New Issue: Lazard sells $287.5 million mandatory at 6.625% dividend, up 20%
|
| 5/5/2005 | CV | Market Commentary: All eyes on autos as GM, Ford downgraded to junk; Lazard new mandatory dips below issue
|
| 5/4/2005 | CV | Market Commentary: GM convertibles soar on Kerkorian news; Lazard at bat; Ivax at 98.5; American Tower buyers seen
|
| 5/2/2005 | CVHY | Fitch to rate Lazard notes BB+
|
| 4/27/2005 | CVHY | Moody's rates Lazard notes, convertibles Ba1
|
| 4/27/2005 | CVHY | S&P rates Lazard notes BBB-
|
| 4/21/2005 | CV | Lazard $250 million mandatory talked with 6.25%-6.75% dividend, up 20%-24%
|
| 4/21/2005 | CV | Market Commentary: BearingPoint suffers 30-point-plus plunge; Lazard terms emerge; Transkaryotic deal slams hedges
|
| 4/18/2005 | CV | Market Commentary: GM lower, but selling lets up; Ford edges up; CNet merger noise resurfaces; Williams, Aquila rise
|
| 3/21/2005 | CV | Market Commentary: GM credit blowout overshadows bounce in stock; Ford's convertible also still skidding; Lazard emerges
|
| 3/21/2005 | CVPP | Lazard adds $287.5 million mandatory to IPO plans
|
| 12/17/2004 | CV | Market Commentary: IVAX reoffered at 98.5; BearingPoint up to 101.25; Charter up on M&A talk; PSEG soars on buyout buzz
|
| 10/5/2004 | CV | Market Commentary: General Mills issue rises; Chiron, Henry Schein fall on flu scare but MedImmune gains
|
